- Home
- GDO vs PLX Comparison
GDO vs PLX Comparison
Compare GDO & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDO
- PLX
- Stock Information
- Founded
- GDO 2009
- PLX 1993
- Country
- GDO United States
- PLX Israel
- Employees
- GDO N/A
- PLX N/A
- Industry
- GDO Finance Companies
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GDO Finance
- PLX Health Care
- Exchange
- GDO Nasdaq
- PLX Nasdaq
- Market Cap
- GDO 169.4M
- PLX 160.2M
- IPO Year
- GDO N/A
- PLX 1998
- Fundamental
- Price
- GDO $11.27
- PLX $2.22
- Analyst Decision
- GDO
- PLX
- Analyst Count
- GDO 0
- PLX 0
- Target Price
- GDO N/A
- PLX N/A
- AVG Volume (30 Days)
- GDO 39.4K
- PLX 553.9K
- Earning Date
- GDO 01-01-0001
- PLX 03-13-2025
- Dividend Yield
- GDO 9.81%
- PLX N/A
- EPS Growth
- GDO N/A
- PLX N/A
- EPS
- GDO N/A
- PLX N/A
- Revenue
- GDO N/A
- PLX $45,667,000.00
- Revenue This Year
- GDO N/A
- PLX N/A
- Revenue Next Year
- GDO N/A
- PLX $90.00
- P/E Ratio
- GDO N/A
- PLX N/A
- Revenue Growth
- GDO N/A
- PLX N/A
- 52 Week Low
- GDO $11.21
- PLX $0.82
- 52 Week High
- GDO $13.04
- PLX $2.36
- Technical
- Relative Strength Index (RSI)
- GDO 48.59
- PLX 74.10
- Support Level
- GDO $10.92
- PLX $2.11
- Resistance Level
- GDO $11.25
- PLX $2.36
- Average True Range (ATR)
- GDO 0.12
- PLX 0.12
- MACD
- GDO 0.03
- PLX 0.00
- Stochastic Oscillator
- GDO 85.37
- PLX 77.42
About GDO Western Asset Global Corporate Defined Opportunity Fund Inc.
Western Asset Global Corp Defined Opp is a closed-end management investment company with a primary investment objective to provide current income. Its secondary objective is to seek capital appreciation. The Fund invests in the United States and foreign corporate fixed-income securities of varying maturities.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.